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Abstract Comparative allelotyping of the short arm of human 
chromosome 3 (3p) in four types of epithelial carcinomas was 
performed using an identical set of polymorphic markers. In 
total, 117 samples of non-papillary renal cell carcinoma (RCC), 
non-small cell lung carcinoma (NSCLC), carcinoma of uterine 
cervix (CC), and breast carcinoma (BC) were screened for loss of 
heterozygosity (LOH) with 10 di-, tri- and tetrameric markers 
covering nine bands of 3p. High LOH frequencies were detected 
in at least one locus: RCC (36143, 84%), BC (20/26, 77%), 
NSCLC (16124, 67%), and CC (15124, 62%). Small interstitial 
deletions prevailed in BC and CC whereas large continuous and 
discontinuous deletions were mainly found in RCC and NSCLC. 
Different epithelial tumors displayed unique LOH profiles with 
partial overlaps in 3p26.1, 3p21.31, and 3p13. The overlap 
around D3S2409 (3p21.31) appeared common for RCC, BC and 
CC. 
© 1999 Federation of European Biochemical Societies. 
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1. Introduction 
Allele losses in the short arm of human chromosome 3 (3p) 
were found to be common in various epithelial tumors includ- 
ing kidney, lung, uterine cervix and mammary gland carcino- 
mas (reviewed in [1]). The crucial role of chromosome 3p was 
shown directly by detection of tumor suppressor activity in 
microcell-mediated transfer experiments for regions 3p12-p14 
and 3p21-p22, as well as for the VHL gene, located in 3p26.4 
(reviewed in [1,2]). Cytogenetic analyses and allelotyping of 
chromosome 3p in primary, metastatic and benign tumors as 
well as in preinvasive neoplasia have suggested that 3p dele- 
tions are early events in the pathogenesis of various epithelial 
carcinomas including renal cell carcinoma (RCC) [3], small 
cell lung carcinoma (SCLC), non-small cell lung carcinoma 
(NSCLC) [l,4], carcinoma of uterine cervix (CC) [5 8], and 
breast carcinoma (BC) [9-11]. Until now the VHL gene re- 
mains the only candidate gene in 3p for which tumor suppres- 
sor function was well documented (see references in [1]). 
In order to find new candidate loci for tumor suppressor 
genes (TSG) a detailed analysis of overlapping deletions was 
performed for various cancer types: nasopharyngeal c rcino- 
ma [12], RCC [2,13 18], CC [19], BC [20,21], lung [22,23] and 
epithelial ovarian tumors [24]. Overlapping of allele and ho- 
mozygous deletions was detected not only within one type of 
malignancy, but also between different ypes, for example be- 
tween RCC and SCLC (reviewed in [1]). Homozygous dele- 
tions found in region 3p21.31 in the SCLC cell lines NCI- 
H740, NCI-HI450 and GLC20 [25] and in uncultured tumors 
[22] were shown to overlap with a homozygous deletion de- 
tected in mammary gland cell line HCC1500; these results 
made it possible to narrow the candidate TSG locus up to 
120 kbp [21]. This deletion, as well as homozygous deletion in 
region 3p12 found for the SCLC U2020 cell line, appeared to 
overlap with the subchromosomal fragment suppressed tu- 
morigenicity of RCC cell lines which was detected via micro- 
cell fusion [18,26]. These results suggest he existence of at 
least one TSG common for different types of cancer and 
show that comparative mapping of 3p in various malignancies 
is important for further identification of candidate TSG. 
Earlier [27] chromosome 3p was allelotyped in 40 samples 
of RCC, endometrial nd ovarian tumors applying six tri- and 
tetrameric markers, and an identical set of markers proved 
useful for comparative mapping of a certain chromosome in 
various malignancies. In this study we applied a panel of l0 
tetra-, tri- and dinucleotide markers for allelotyping of 3p in 
117 samples of RCC, NSCLC, CC, and BC aiming to study 
the involvement of 3p loci in epithelial carcinomas of different 
location. 
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2. Materials and methods 
2.1. DNA samples 
Forty-three non-papillary (including 33 clear cell) RCC samples, 
24 NSCLC (16 squamous cell) samples, 26 BC (16 duct) samples 
and 24 squamous cell CC samples were used for DNA isolation. 
Samples of frozen tumor tissues were stored at 70°C. Top and 
bottom sections (10 gm thick) were stained with hematoxylin and 
eosin and examined under the microscope. Selected samples contain- 
ing 60% or more tumor cells, and matched normal tissues were cut 
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into 20-1~m sections for DNA extraction. High-molecular-weight 
DNA was isolated by the standard procedure with proteinase K treat- 
ment at 37°C for 24 h followed by phenol/chloroform extraction and 
precipitation with ethanol [28]. The DNA preparations were tested by 
electrophoresis in 1% agarose gel. 
2.2. PolymotT)hic markers, PCR and lo.sw o/" heterozygosity (LOH) 
evaluation 
Ten markers were chosen from the GDB and CHLC data bases for 
the nine large cytogenetic bands of 3p on the basis of heterozygosity, 
location and allele length of polymorphic loci. To avoid CA repeat 
shadows (see references in [11]), mainly tri- and tetrameric markers 
(seven loci) were used in combination with non-denaturing 8 12% 
20-cm PAGE and silver staining. CA repeat markers were selected 
to obtain amplification products of size 80 170 bp and sufficient res- 
olution for alleles different in 2 bp. Denaturing 6.5% 40-cm PAGE 
in combination with 32p-labeled primers and subsequent autoradiog- 
raphy was also applied for ambiguous LOH cases in dinucleotide loci. 
The order of the selected markers according to the LDB (http:// 
www.cedar.genetics.soton.ac.uk/pub/chrom3/gmap) is: D3S2405 
(GGAT2A11)-D3S 1286-D3S3047 (GATA85F02)-D3 $3527-D3S2420 
(ATA25A07)-D3S2409 (ATA 1 OH 11)-D3S1766 (GATA6F06)- 
D3SI481-D3S2454 (GATA52H09)-D3S2406 (GGAT2G03). For tri- 
and tetrameric markers short CHLC names showing microsatellite 
motifs are given in parentheses. The location of the nmrkers on 3p 
is shown in Tables 1 3 and Fig. 2. 
The PCR primers were synthesized in the laboratory of Dr. V.P. 
Veiko (Russian State Genetics Center, Moscow). The PCR reaction 
mixture (25 ml) consisted of 10 pmol of each primer, 50 ng of tem- 
plate DNA, 1 U of Ta@ DNA polymerase (Biotech, Moscow), 
0.2 mM each of dNTP, 67 mM Tris-HC1, pH 8.8, 1.0-2.5 mM MgCI2, 
16.7 mM (NH4)2SO4 and 0.01% Tween-20. The samples were pro- 
cessed through 30 cycles comprising 1rain denaturation at94°C, 1 rain 
at the appropriate annealing temperature and 1 min at 72°C. in a 
Techne PHC-3 thermal cycler. Annealing temperatures and MgCle 
concentrations were used according to the GDB data. 
Band intensities for PCR products of high- and low-molecular- 
weight alleles were compared. The LOH was scored when a ratio of 
intensities for matched tumor and normal DNAs differed two-fold or 
more. The LOH data were analyzed by three independent viewers; 
deviation of LOH profiles was calculated using three sets of observa- 
tions. 
3. Results 
3.1. Allelotype patterns of 3p in RCC, NSCLC, BC, and CC 
samples 
Fig. 1 shows representat ive examples o f  LOH for the RCC 
and BC samples in tetrameric GGAT and tr imeric AAT  loci. 
Appl icat ion of  tri- and tetrameric markers  combined with 
non-denatur ing  8 12% PAGE and silver staining al lowed us 
to separate the PCR products  with sufficient resolution. The 
high-molecular-weight  allele is lost in RCC samples 171, 146, 
Table 1 
Allelotyping of 3p in NSCLC tumors 
D3S2406 
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Fig. 1. Examples of tri- and tetranucleotide analysis of tumor 
DNAs with non-denaturing PAGE followed by silver staining, a: 
PCR products of some RCC samples in the D3S2406 GGAT repeat 
locus, separated through 8% PAGE; markers of electrophoresis mo- 
bility (M), fragments of pUC19/Msiol (404, 331 bp). b: PCR prod- 
ucts of some RCC samples in the D3S2405 GGAT repeat locus, 
separated through 12'/o PAGE: M, pBR322/Alul (100 bp). c: PCR 
products of some BC samples in the D3S2409 AAT repeat locus, 
separated through 12% PAGE; M, pUC19/MspI (111, 110 bp). 
and 147 and in BC samples 150, 151, and 155 (Fig. l). The 
low-molecular-weight allele is lost in RCC samples 170, 174, 
and 143. 
Al le lotyping of  3p in NSCLC samples is shown in Table I. 
Allelic alterations were revealed in 16 out o f  24 samples. More  
than half  o f  these alterations (10 out o f  16 samples) are total 
losses o f  one allele o f  the whole short  3p arm. Sample 179 
exhibited a partial terminal  deletion. Short  interstit ial dele- 
t ions were detected in samples 14 and 55. Mult iple discont in-  
uous deletions separated by loci with retained heterozygosity 
were found in samples 15, 40, and 99. Microsatel l i te instabil ity 
Marker Cytogenetic location Sample No. 
5 23 38 39 50 60 67 100 130 162 40 15 179 99 14 55 
D3S2405 3p26.1 • • ni • ni • • • • • • ni • ni (3 (3 
D3S1286 3p25.2 • • • • • • • • • • (3 • • • • (3 
D3S3047 3p24.3 • • • • • • ni • ni • • ni • (3 ni • 
D3S3527 3p21.33 ni • • • • • • • • • • ni ni ni (3 © 
D3S2420 3p21.31 • ni • • • ni • • • ni • ni • • (3 (3 
D3S2409 3p21.31 • • ni • • ni ni • • ni • • ni • (3 ni 
D3S1766 3p21.1 • • • ni ni ni ni • • • • • O ni (3 ni 
D3S1481 3p14.2 • MI • • • • • • • • • O ni (3 (3 (2) 
D3S2454 3pl 3 ni • • ni • • ni ni ni ni ni • (3 ni (3 ni 
D3S2406 3p12.2 ni ni • ni • ni ni ni ni • • • ni ni (3 (3 
O, loss of heterozygosity; ©, retained heterozygosity; hi, non-informative; MI, microsatellite instability; only cases with detected a11elic altera- 
tion are shown. 
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(MI) was detected only in locus D3Sl481 in NSCLC sample 
23. 
Allelic losses in CC samples (Table 2) were revealed in 15 
out of 24 samples with frequency similar to NSCLC. How- 
ever, losses of the whole 3p arm from one chromosome ho- 
molog were observed only in four cases (244, 415, 436 and 
424) out of 15 and a partial terminal deletion was seen in one 
sample, 275. Six cases (458, 86, 248, 234, 451 and 418) dem- 
onstrated discontinuous multiple deletions of different length 
and in four other cases (407, 88, 289, and 235) short intersti- 
tial deletions were found. Ten MI cases were detected in five 
CC samples (424, 458, 86, 235 and 459). 
Allelotyping of 3p in four epithelial tumors has shown two 
patterns: one with a considerable contribution of the large 
continuous and discontinuous deletions for NSCLC (Table 
1) and RCC (data not shown) and the other with shorter 
interstitial and multiple deletions for CC (Table 2) and BC 
(data not shown). 
Allelic alterations of the MI type were observed not as 
frequently as LOH: one event in one NSCLC sample (Table 
1), 10 events in four RCC samples (not shown), 10 events in 
five CC samples (Table 2) and 16 events in five BC samples 
(not shown). 
3.2. Frequencies of allelic alterations 
Allelic deletions detected by LOH in at least one locus were 
highly represented in all studied tumors: RCC (36 samples 
with LOH from 43 samples studied, 84%), NSCLC (16/24, 
67%), BC (20/26, 77%) and CC (15/24, 62%). 
The allelotyping data for 43 samples of RCC, 24 samples of 
NSCLC, 26 samples of BC, and 24 samples of CC were used 
to calculate the LOH frequencies for the 10 loci of 3p. Each of 
the polymorphic markers was scored for the number of LOH 
cases divided by the number of informative cases. The results 
obtained for four groups of carcinomas are summarized in 
Table 3. These data demonstrate that average LOH frequen- 
cies in the 3p loci are two times higher in RCC (62%) and 
NSCLC (55%) than in CC (29%) and BC (27%) samples. The 
higher LOH frequency in the 3p loci in RCC and NSCLC is 
consistent with the considerable contribution of elongated 
continuous and discontinuous deletions in these tumors, in 
contrast to BC and CC with shorter interstitial allele dele- 
tions. Therefore, according to the type and the size of dele- 
tions epithelial carcinomas may be divided into two groups: 
with large deletions and high frequency of LOH in the 3p 
loci (RCC and NSCLC) and with short interstitial deletions 
Table 2 
Allelotyping of 3p in cervical tumors 
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Fig. 2. 3p LOH profiles for RCC, NSCLC, CC, and BC. LOH fre- 
quency (Table 3) vs. the map of 3p. Values of LOH frequency for 
the nine markers related to the nine 3p bands were used. Distances 
between the markers are shown in accordance with the LDB map. 
Deviation for three independent viewers is shown. 
and a two-fold lower frequency of LOH in the 3p loci (CC 
and BC). 
DNAs with M! in one or more loci comprise from 4% (1/ 
24) for NSCLC, 12% (5/43) for RCC, 15% (4/26) for BC up to 
20.8% (5/24) for CC. This is considerably less than the fre- 
quency of cases with LOH (62-84%). Replication error (RER) 
phenotypes (see references in [1]), detected by two or more MI 
events found for 10 loci, were observed with a frequency of 
7 8% in RCC (3/43), BC (2/26) and CC (2/24). Interestingly, 
most samples with single MI and all samples with an RER 
phenotype exhibited LOH. Presumably, there is a positive 
rather than negative correlation between LOH and MI events 
on 3p. 
3.3. 3p LOH profiles jbr various carcinomas 
The LOH frequencies taken from Table 3 are presented in 
Fig. 2. The much higher location of the RCC and NSCLC 
profiles clearly demonstrates higher LOH frequencies in these 
tumor types for each of the markers. In the RCC and NSCLC 
profiles telomeric peaks (75%) are higher than in centromeric 
loci (50%). High LOH frequencies in telomeric loci are related 
to the contribution of terminal deletions of different size and 
Marker Cytogenetic location Sample No. 
244 415 436 424 458 86 248 234 418 275 451 235 289 88 407 459 
D3S2405 3p26. l • ni • • ni ni • • O • • O O O ni ni 
D3S1286 3p25.2 ni • ni • • M1 O O O ni O ni O • O MI 
D3S3047 3p24.3 ni • ni MI MI • O ni • ni ni ni O O ni ni 
D3S3527 3p21.33 • • • MI O • • ni O • O O O O O O 
D3S2420 3p21.31 • • • • • ni • • Q O Q MI O ni • ni 
D3S2409 3p21.31 • • ni • • MI O O • O ni • • O © ni 
D3S1766 3p21.1 ni • ni ni ni ni • O ni Q ni © © © O O 
D3S1481 3pl4.2 ni • • MI ni Q © O © O • © © © Q O 
D3S2454 3p13 ni ni • MI ni ni ni ni ni O ni O ni ni O ni 
D3S2406 3p12.2 • • • M1 • • © O O ni • O © O O © 
O, loss of heterozygosity; O, retained heterozygosity; ni, non-informative; MI, microsatellite instability; only cases with detected allelic altera- 
tion are shown. 
218 
Table 3 
Frequencies of LOH in 3p loci in four tumor types 
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Marker Cytogenetic location RCC NSCLC BC CC 
D3S2405 3p26.1 23/31, 74% 10/19, 52% 4/15, 27% 7/20, 35% 
D3S1286 3p25.2 20/29, 69% 14/23, 60% 5/19, 26% 4/17, 24% 
D3S3047 3p24.3 16/27, 59% 11/15, 73% 2/12, 17% 3/12, 25% 
D3S3527 3p21.33 18/30, 60% 10/16, 62% 5/18, 28% 6/18, 33°/,, 
D3S2420 3p21.31 17/25, 68% 10/18, 55% 4/19, 21% 8/19, 42% 
D3S2409 3p21.31 14/18, 78% 9/15, 60% 9/22, 41% 7/t 6, 44% 
D3S1766 3p21.1 15/19, 79"/0 8/17, 47% 5/17, 29"/0 2/13, 15% 
D3S1481 3p14.2 8/16, 50% 10/20, 50% 3/19, 16% 3/20, 15% 
D3S2454 3p13 8/16, 50% 5/10, 50% 6/16, 38% 1/7, 14% 
D3S2406 3p12.2 12/31, 39% 5/13, 38% 5/20, 25% 6/22, 27% 
Average 151/242, 62% 92/166, 55% 48/177, 27% 47/164, 29% 
The number of LOH cases/informative cases, % are shown. 
possible involvement of VHL or other candidate TSG in tu- 
morigenesis. 
The 3p LOH profiles for different epithelial tumors ap- 
peared to be distinguishable (Fig. 2). The NSCLC profile 
showed a major peak in 3p24.3 (D3S3047) and additional 
regions of high LOH around D3S2409 (3p21.31) and 
D3S2454 (3p13). The RCC profile possessed a major peak 
encompassing two cytogenetic bands, 3p21.31(D3S2409) and 
3p21.1 (D3S1766), and high deletion frequencies in 3p26.1 
(D3S2405) and in 3p13 (D3S2454). The BC LOH profile in- 
cluded regions of high LOH around D3S2409 (3p21.31) and 
D3S2454 (3p13). The CC profile had a region of high LOH 
around D3S2409 (3p21.31) and D3S2405 (3p26.1). 
Partial overlaps may be seen in certain 3p regions. Overlap 
around D3S2409 (3p21.31) seems to be common for at least 
three malignant neoplasias: RCC, CC and BC (Fig. 2). Addi- 
tional overlaps were found in telomeric region 3p26.1 
(D3S2405) for RCC and CC, and in 3p13 (D3S2454) for 
RCC, NSCLC, and BC. The loci D3S1766 in 3p21.1 and 
D3S3047 in 3p24.3 were typical for RCC and NSCLC, respec- 
tively. 
4. Discussion 
The problem of involvement of different chromosomes in
the development of certain cancer types was studied using 
comparative cytogenetic and LOH approaches for RCC 
[29,30], adenocarcinoma and squamous cell carcinoma of 
the lung [3,31], invasive CC [32 34], and BC [11]. An extensive 
karyotyping of 3185 tumors [35] included both analysis of the 
contribution of various chromosomes in a certain type of 
malignancy and the detection of damage of a certain chromo- 
some for various types of cancer. These data may serve as a 
guide for more detailed molecular studies. However, no com- 
parative allelotyping analyses were performed until now for a 
certain chromosome and various types of malignancies. 
Mapping of human chromosome 3p using the LOH strat- 
egy was performed for epithelial tumors of various locations 
by several research groups. The results on the character of 
deletions and on the regions most affected by deletions are 
often rather controversial even within one form of malig- 
nancy, for example RCC [14-16]. This diversity may be ex- 
plained by different procedures used for evaluation of LOH 
and for selection of material (short-term cell lines were used 
only by one group [14]) and by different sets of markers. For 
example, 2 3 different markers were applied for telomeric re- 
gion 3p26 p25 in each of the three above-mentioned studies 
[14-16]: only one marker (D3S1560) was coincident in the two 
studies. 
This work presents the first comparative allelotyping study 
of human chromosome 3p in different malignancies with iden- 
tical set of the markers and identical procedures for selection 
of material and processing of the LOH data. These compar- 
isons have revealed critical 3p regions for each form of the 
malignancy and regions of their overlapping. 
Common features may be seen in the cytogenetic profiles of 
3p deletions [35] and in the LOH profiles obtained in this 
work. For example, in both cases (compare Fig. 2 and the 
chromosome 3 profile from [35]) the main peak for RCC is 
more centromeric than the critical region for lung carcinoma. 
Our results are consistent with the earlier data on 3p alle- 
lotyping obtained for certain types of tumors. For example, 
the frequencies of allelic deletions detected by the LOH anal- 
ysis in at least one 3p locus were 62% and 77% for CC and 
BC, respectively; this is close to the data for CC (70% [19]) 
and BC (52% [20]). The LOH frequency for various markers 
varied from 15 to 45% [20] and from 16 to 41% in this work; 
26% and 29%, respectively, for the common D3S1286 marker. 
Our results are in good agreement with the data [13,15,16], 
showing a considerable contribution of discontinuous multiple 
deletions in the development of RCC. 
The frequencies of MI events (12-21%) and RER pheno- 
type (7 8%) found here for RCC, BC and CC are consistent 
with earlier observations [11,15,34]. The low incidence of MI 
in NSCLC has already been mentioned [22]. The positive cor- 
relation between LOH and RER shown here for the 3p region 
may be related to the deletion of the MLH1 repair system 
gene located in 3p22 p21.33 (see references in [1]'). 
New candidate loci for genes associated with cancer were 
found in several regions of 3p. The locus localized around 
D3S2409 (3p21.31) seems to be common for at least three 
epithelial carcinomas. According to the LDB map the new 
candidate locus is centromeric to both known homozygous 
deletion regions found earlier in 3p21.3 [22,25,36 38]. 
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